Parkinson’s Disease (PD) is a chronic, progressive neurodegenerative disease that affects the basal ganglia (Sethi KD 2002). Parkinson’s is characterized by tremor, rigidity, bradykinesia, and muscle stiffness (Chiurchiù et al 2015). The loss of melanin¬ containing nigral neurons leads to abnormal dopaminergic transmission, with tremor evolving as a consequence of subthalamic over activity (García ¬Arencibia et al 2002).
The main histopathological hallmark that is seen post mortem is the presence in the surviving neurons of protein aggregates known as Lewy bodies.
The increase in the levels of endocannabinoids and the alteration in both CB1R and CB2R expression in different stages of Parkinson’s unlocks the possibility of manipulating these receptor functions in order to manage the disease (Lastres ¬Becker et al 2001). Studies have demonstrated that, in the early stages of Parkinson’s, CB1R receptors are downregulated, while in advanced and symptomatic phases there is a switch to CB1R upregulation (García¬Arencibia M et al 2009).
Impact of Parkinson’s
Parkinson’s affects 1 million people in the U.S. and 10 million worldwide. The economic burden of Parkinson’s is at least $14.4 billion a year in the United States, and the prevalence of Parkinson’s will more than double by the year 2040 (The Current and Projected Economic Burden of Parkinson’s Disease in the United States).
Serosapse and Our Patent Filing
Serosapse, is our patent pending formulation that uses tetrahydrocannabinol (THC), cannabidiol (CBD) and other natural ingredients.